Epix MS-325 User Fee Goal Is Oct. 15; Broad Vascular Imaging Claim Sought
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s decision to assign Epix’s vascular imaging agent MS-325 a standard review sets the user fee goal for the NDA at Oct. 15.